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Cytomegalovirus infection and risk of preeclampsia:  
A meta-analysis of observational studies 
 
 
Abstract 
Background: Cytomegalovirus (CMV) infection is one of the most common infectious 
diseases in pregnant women in terms of global impact and is related with many adverse 
health consequences during pregnancy. For the first time, we performed a systematic 
review and meta-analysis study to evaluate the possible association between CMV 
infection and preeclampsia (PE). 
Methods: A comprehensive literature search to identify the relevant papers published 
earlier than February 2018 was performed in PubMed, ISI (Web of Science), Google 
Scholar and SCOPUS databases. We followed the PRISMA (preferred reporting items for 
systematic reviews and meta-analyses) guidelines for design, analysis and interpretation of 
results.  Pooled odds ratio (OR) and 95% confidence intervals (CI) were estimated using a 
random-effects meta-analysis model. Heterogeneity was assessed with Q-test and I
2
 
statistics. 
Results: A total of 13 studies including 6158 pregnant women (2734 women with PE and 
3424 healthy controls) met the eligibility criteria. The results of meta-analyses based on 
PCR (OR: 3.09; 95% CI:0.72–13.24; I2=57.3%), IgG-ELISA (OR: 1.24; 95% CI:0.83–
1.85; I
2
=71%) and IgM-ELISA (OR: 1.04; 95% CI:0.66–1.65; I2=0.0%) demonstrated that 
CMV infection could not be a potential risk factor for PE. 
Conclusions: In conclusion, results of the present study demonstrated that CMV infection 
could not be a potential risk for developing PE. More epidemiological and experimental 
studies are needed to investigate the impact of CMV infection on the development of PE. 
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Preeclampsia (PE), a pregnancy-specific multisystem vascular disorder, is globally 
responsible for many maternal and perinatal deaths and complications, as it affects 2%- 
8% of pregnancies (1). It generally occurs during the second half of pregnancy and 
characterized by new-onset gestational hypertension, generalized vascular dysfunction and 
proteinuria (2). Etiology of the disease is still unclear, although it is hypothesized that PE 
can be resulted from placental malperfusion due to abnormal remodeling of maternal spiral 
arteries, and both of maternal and fetal components are involved in the development of the 
condition (3). Moreover, it is demonstrated that PE is associated with disturbance in the 
levels of angiogenic factors including soluble fms-like tyrosine kinase 1 (sFlt-1) and 
placental growth factor (PlGF) (4, 5). Furthermore, some studies showed that PE is related 
with increased levels of maternal circulating cytokines such as TNF- α, IFN- γ, IL- 10 and 
IL- 6 (6, 7). In the last two decades, there is growing evidence that bacterial, viral and 
parasitic infectious agents and their related inflammatory responses are implicated in the 
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pathophysiology of PE (1, 8, 9). Cytomegalovirus (CMV), a ubiquitous beta herpes virus, 
is globally one of the most common congenital infectious agents during pregnancy. 
CMV is responsible for a broad range of disabilities in 
newborns, such as visual impairment, sensorineural hearing 
loss, and motor and cognitive deficits. In pregnant women, 
clinical symptoms of CMV infection is generally nonspecific 
and resemble a mononucleosis- or flu-like syndrome, with 
fever, sore throat, cervical lymphadenopathy, myalgia, and 
fatigue (10, 11).  
Moreover, it is demonstrated that CMV infection is a 
potential risk factor for the development of hypertension and 
cardiovascular disease (12). In the past two decades, several 
observational and experimental studies have investigated the 
possible relationship between CMV infection and the 
development of PE in pregnant women. However, the 
majority of studies demonstrated conflicting results together 
and to date, it remains unknown whether women with CMV 
infection are at increased of developing preeclampsia or not; 
therefore, for the first time we designed this systematic 
review and meta-analysis study in an attempt to a better 
understanding of a possible link between CMV infection and 
development of PE. 
 
 
Methods 
Study design: For this meta-analysis study, we followed the 
PRISMA (preferred reporting items for systematic reviews 
and meta-analysis) guidelines for design, analysis and 
interpretation of results. The exposure for our study was 
serological or molecular evidence of CMV infection and the 
main outcome of interest was developing PE in infected 
women and compared with healthy controls. To prevent 
common biases during the literature research, language, 
geographical area or date restrictions were not applied. All 
observational (cross-sectional, cohort, or case–control) 
studies that evaluated the CMV infection status among 
women with PE and healthy controls were included in the 
present meta- analysis.  
PE is defined as a systolic blood pressure ≥ 140 mm by 
the American College of Obstetricians and Gynecologists 
(ACOG) criteria (13) and CMV infection is measured by the 
detection of serum CMV-specific IgG or IgM using 
serological methods and DNA-based detection molecular 
methods. We excluded case- reports, experimental studies 
and non-original papers (review, systematic reviews, 
editorials, or letters). 
Search strategy and study selection: A comprehensive 
literature search for identifying the relevant papers published 
earlier than February 2018 was performed in PubMed, ISI 
(Web of Science), Google Scholar and SCOPUS databases. 
Our search was done by using the combination of the 
following keywords: “Cytomegalovirus”, “Cytomegalovirus 
infection”, “CMV”, “preeclampsia”, “eclampsia”, “gestosis”, 
“pregnancy hypertension” and “gestational hypertension”, 
with the Boolean operators “OR” and/or “AND”. Finally, 
our search was complemented by reviewing the reference 
lists of the electronically retrieved full-text papers and 
related reviews. Our search strategy is schematically 
presented in the PRISMA flow diagram (figure 1 and 
supplementary figure 1). 
Data extraction and study quality assessment: After 
duplicate removal, two researchers (Z.G. and A.R) 
independently assessed the full text of eligible studies and 
information was extracted using Microsoft Excel software. 
The following information was extracted for each study: first 
author, publication year, country, study design, sample size, 
diagnostic method. In case-control studies, matching criteria, 
number of cases and controls and of infected subjects in each 
group were extracted.  
Any uncertainties were resolved by joint review of the 
manuscript and consultation with third researcher (M.N.S) to 
reach consensus. Newcastle-Ottawa scale was used for 
quality assessment of the included studies, as it was used in 
our previously meta-analysis studies (14, 8). This step was 
also done by two researchers (Z.G. and A.R) and 
disagreements were resolved after consultation with third 
researcher (M.N.S). 
Data synthesis and statistical analysis: In this study, meta-
analysis was performed using Stata Version 12 (Stata Corp., 
College Station, TX). The association between CMV 
infection and PE was assessed through generating the pooled 
odds ratio (OR) and 95% confidence intervals (CI) using a 
random effects model.  
In studies where adjusted ORs were presented, they were 
used in preference to crude odds ratio. To assess 
heterogeneity amongst the studies, Q-test and I
2
 methods 
were utilized. Stratified analysis was subsequently 
performed regarding the type of antibodies and methods 
(IgG, IgM and PCR). Publication bias was assessed through 
Egger’s publication bias method for asymmetry.  
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A p-value of less than 0.1 was considered statistically 
significant. Results are presented as forest plots and the 
association between CMV infection and PE is illustrated by 
an OR and 95% CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow chart showing the process of study selection 
 
Results 
Study characteristics: As shown in PRISMA flowchart 
(figure 1), our literature search yielded 2278 articles. After 
duplicate removal and assessment of the titles and abstracts, 
19 studies were reviewed in full text. Of these, six studies 
were excluded after applying inclusion and exclusion 
criteria, and finally 13 articles met the eligibility criteria to 
be included in the meta-analysis (15-27). Among 13 
included studies, eight had a case-control design and five 
were nested case-control studies. The eligible studies were 
performed in seven different countries from three continents 
(nine in America, three in Europe and one in Asia). Two 
studies were based on molecular methods, 11 studies used 
serological methods to detect CMV infection in cases and 
controls. Four studies included reported seroprevalence of 
CMV infection based on the detection of only IgG  
 
antibodies, three on IgM antibodies, and four studies 
screened both the IgG and IgM antibodies for CMV 
infection. A total of 2734 pregnant women with confirmed 
PE were included in these studies. All studies used ACOG 
criteria for the selection of preeclamptic women. As well, the 
included studies recruited a total of 3424 healthy pregnant 
women as controls. The main characteristics for included 
studies are presented in table 1. 
Prevalence of CMV infection among preeclamptic 
women and controls: Overall, the prevalence of CMV 
infection in pregnant women with PE based on PCR, IgG 
and IgM were 40.6% (24/59), 58.8 (1123/1909), and 3.5% 
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(89/2490), respectively. While, the prevalence of CMV 
infection in healthy controls based on PCR, IgG and IgM 
were 21.5% (14/65), 62.1% (1595/2566), and 3.5% 
(74/2099), respectively. 
Table 1:  Summary of studies investigating the association between Cytomegalovirus infection and preeclampsia 
First author/year Ref Country Diagnostic 
Method 
Cases Controls Quality 
score 
Number Infected Number Infected 
Belfort, 1998 15 USA PCR 33 10 36 2 5 
Trogstad, 2001 16 Noewey IgG-ELISA 33 19 945 650 7 
Carreiras, 2002 17 Venezuela PCR 26 14 29 12 6 
Dadelszen, 2003 18 Canada IgG-ELISA 38 30 113 92 6 
Rustvuld, 2005 19 USA IgG-ELISA 48 21 140 60 7 
Xie, 2010 20 USA IgG&IgM-ELISA 78 IgG, 41; IgM, 8 109 IgG, 29; IgM, 7 7 
Strand, 2012 21 Norway IgG&IgM-ELISA 1470 IgG, 819; IgM, 
18 
991 IgG, 578; IgM, 
12 
7 
Zhang, 2012 22 China IgM-ELISA 52 49 34 34 5 
Haggerty, 2013 23 USA IgM-ELISA 509 7 336 4 7 
Haggerty, 2013 24 USA IgM-ELISA 205 4 423 13 5 
Xie, 2014 25 USA IgG&IgM-ELISA 30 IgG, 17; IgM, 3 60 IgG, 22; IgM, 3 5 
Radulescu, 2016 26 Romania IgG-ELISA 66 40 62 26 6 
Alvarado-Esquivel, 
2017 
27 Mexico IgG&IgM-ELISA 146 IgG, 136; IgM, 0 146 IgG, 138; IgM, 1 6 
 
Results of meta-analysis: At first, we performed meta-
analysis regarding the three different methods (PCR, IgG-
ELISA and IgM-ELISA) used in the included studies for the 
detection of CMV infection between cases and controls.  The 
results of meta-analysis based on PCR (OR: 3.09; 95%  
 
CI:0.72–13.24; I2=57.3%), IgG-ELISA (OR: 1.24; 95% 
CI:0.83–1.85; I2=71%) and IgM-ELISA (OR: 1.04; 95% 
CI:0.66–1.65; I2=0.0%) demonstrated that CMV infection 
could not be the potential risk factor for PE (figure 2, A-C).  
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Figure 2: Forest plots for the association between cytomegalovirus infection and preeclampsia. A) Forest plot regarding the 
PCR method, B) Forest plot regarding the IgG-ELISA method, C) Forest plot regarding the IgM-ELISA method 
 
In subgroup analysis regarding the IgG antibody and type of 
studies, a significant relationship was observed in case-
control studies (OR: 1.71; 95% CI:1.04–2.81; I2=54.7%), 
whereas this relationship was not significant in nested case-
control studies (OR: 0.88; 95% CI:0.75–1.03; I2=0.0%) 
(figure 3). Egger’s test was used to detect the possibility of 
publication bias. Based on the symmetry assumption, there 
was no significant publication bias in the studies (figure 4 A 
and B). 
  
regarding the IgG-ELISA method and type of studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Forest plots for the association between cytomegalovirus infection and preeclampsia, result of the subgroup 
analysis 
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Figure 4: Publication bias using Egger’s plot. (A) Publication bias related with IgG-ELISA method. (B) Publication bias 
related with IgM-ELISA method. 
Discussion 
The results of this study demonstrated that women with 
PE have higher rate of CMV infection compared to healthy 
controls, although the statistically significant relationship 
was not observed. Specially we have found higher odds in 
studies that used PCR to detect CMV infection (OR=3.09), 
although the number of studies was very low (two studies). 
We guess if more molecular studies were available, it was 
possible that significant correlation would be found. Higher 
odds found in PCR studies could be due to higher sensitivity 
and specificity of PCR-based methods compared to 
serological methods. 
Although it should be more investigated, since several 
potential mechanisms could be involved in the association 
between CMV infection and the development of PE. 
Endothelial-platelet dysfunction and acute atherosis in 
arterial wall resulting from CMV infection can lead to 
uteroplacental ischemia, a key pathogenic condition to the 
development of PE (28, 29). Further, CMV infection could 
stimulate the release of immune inflammatory mediators 
including, tumour necrosis factor alpha (TNF-α), interferon 
gamma (IFN-γ), interleukines (IL-4, IL-8, IL-18), 
neutrophils and is related with upregulated expression of 
TLR-2, and TLR-4 (26, 30-32).  
Several studies have demonstrated that the shift of 
immunological cytokine profile of Th2 toward Th1 and high 
levels of pro-inflammatory cytokines have important role in 
the onset of PE (1, 33, 34). Moreover, increasing evidence 
has shown that the extent of neutrophil activation and 
upregulated TLR expression can be linked with the 
pathogenesis of PE (32, 35).  
In addition, it is demonstrated that CMV infection can 
modify adhesion molecules such as VCAM-1 (vascular cell 
adhesion molecule-1) and ICAM-1 (intercellular adhesion 
molecule-1) and E-selectin which is related with the increase 
of matrix metalloproteinase (MMP-2) activity and fms-like 
tyrosine kinase-1 (sFlt-1), that can cause alteration in vessel 
remodeling, infiltration of inflammatory cells and the 
development of PE (36, 26). 
The strength of our study includes rigorous methodology, 
the use of ACOG criteria to identify the cases in all studies, 
well-defined matching criteria for controls, and subgroup 
analysis considering the type of studies and diagnostic 
methods. Yet like our previous meta-analysis studies (14, 8), 
this study was limited by the fact that, low number studies 
with mostly low sample size were available in this issue. 
Additionally, most of the included studies have a case-
control design, while other type of observational studies like 
cohorts could be more useful to better understand possible 
relationship. Another limitation is the fact that the results of 
the present meta-analysis are based on the data from studies 
with different methodological characteristics, and different 
cut-offs in serological methods, however we used random 
effects to overcome these limitations. Moreover, like our 
previous study on Helicobacter pylori and the developing of 
PE (8), the present study was also copied with regard to the 
results without adjustment for potential confounders in some 
included studies and restricted geographical areas (America, 
Europe and one study in Asia). Furthermore, since CMV 
infection is ubiquitous and determining IgG is not a reliable 
method for CMV primary infection, therefore, it can be a 
source of heterogeneity in the current study. 
In conclusion, the findings of the present study 
demonstrated that CMV infection could be a potential risk 
for developing PE. More epidemiological studies (especially 
longitudinal studies using both molecular and serological 
methods) are needed to investigate the impact of CMV 
infection or its eradication on the risk of developing PE. 
Besides, more experimental studies should be done to 
identify the exact involved pathways. The GRADE for this 
study is this fact that further researches are very likely to 
have an important impact on our estimated effect and is 
likely to change the estimate.  
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